3.15 USD
▼-0.34-9.63%
盘后 3.21 0.00%
2026-11-20
市值
$87.48M
市盈率
—
EPS
-1.93
股息率
—
52 周区间
2.50 – 11.38
成交量
97.74K
Beta
—
目标价
17.00
52W 低 2.5052W 高 11.38
价格走势
公司简介
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra...